PYC Therapeutics Ltd
ASX:PYC

Watchlist Manager
PYC Therapeutics Ltd Logo
PYC Therapeutics Ltd
ASX:PYC
Watchlist
Price: 1.45 AUD 2.84% Market Closed
Market Cap: 676.6m AUD
Have any thoughts about
PYC Therapeutics Ltd?
Write Note

Relative Value

The Relative Value of one PYC stock under the Base Case scenario is 1.1 AUD. Compared to the current market price of 1.45 AUD, PYC Therapeutics Ltd is Overvalued by 24%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

PYC Relative Value
Base Case
1.1 AUD
Overvaluation 24%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
65
vs Industry
31
Median 3Y
123.3
Median 5Y
140.9
Industry
7.6
Forward
77.5
vs History
vs Industry
Median 3Y
-74.3
Median 5Y
-164.5
Industry
22.1
Forward
-162
vs History
vs Industry
Median 3Y
-67.6
Median 5Y
-201.5
Industry
21.9
vs History
vs Industry
Median 3Y
-66.2
Median 5Y
-189
Industry
23.4
vs History
85
vs Industry
5
Median 3Y
50.3
Median 5Y
65.1
Industry
2.5
vs History
65
vs Industry
27
Median 3Y
121.5
Median 5Y
139.1
Industry
7.5
Forward
70
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
9.3
vs History
vs Industry
Median 3Y
-70.6
Median 5Y
-143.5
Industry
4.2
Forward
-11.8
vs History
vs Industry
Median 3Y
-70.6
Median 5Y
-143.5
Industry
4
Forward
-11.7
vs History
vs Industry
Median 3Y
-67
Median 5Y
-198.2
Industry
5.9
vs History
vs Industry
Median 3Y
-65.9
Median 5Y
-188.9
Industry
3.9
vs History
82
vs Industry
4
Median 3Y
145.8
Median 5Y
286.1
Industry
4.5

Multiples Across Competitors

PYC Competitors Multiples
PYC Therapeutics Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
AU
PYC Therapeutics Ltd
ASX:PYC
684.7m AUD 30 -18.1 -16.5 -16.5
FR
Pharnext SCA
OTC:PNEXF
6T USD 38 027 714.7 -180 740.1 -219 476 -216 971.5
US
Abbvie Inc
NYSE:ABBV
310.3B USD 5.6 61.1 15.2 23.4
US
Amgen Inc
NASDAQ:AMGN
141.6B USD 4.4 33.5 16 30.4
US
Gilead Sciences Inc
NASDAQ:GILD
115.3B USD 4.1 915.4 10.2 10.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
102.4B USD 9.6 -213.4 21 22.1
US
Epizyme Inc
F:EPE
94.1B EUR 1 852.6 -472.7 -514.8 -501.1
AU
CSL Ltd
ASX:CSL
134.4B AUD 5.7 31.8 19.7 24.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.3B USD 5.6 16.6 15.1 16.7
US
Seagen Inc
F:SGT
39.3B EUR 17.8 -54.7 -58.8 -53
NL
argenx SE
XBRU:ARGX
35.7B EUR 19.2 -134.7 -108.7 -79.2
P/S Multiple
Revenue Growth P/S to Growth
AU
PYC Therapeutics Ltd
ASX:PYC
Average P/S: 3 457 242.6
30
63%
0.5
FR
Pharnext SCA
OTC:PNEXF
38 027 714.7
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.6
20%
0.3
US
Amgen Inc
NASDAQ:AMGN
4.4
26%
0.2
US
Gilead Sciences Inc
NASDAQ:GILD
4.1
10%
0.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.6
34%
0.3
US
E
Epizyme Inc
F:EPE
1 852.6
N/A N/A
AU
CSL Ltd
ASX:CSL
5.7
23%
0.2
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.6
23%
0.2
US
S
Seagen Inc
F:SGT
17.8
118%
0.2
NL
argenx SE
XBRU:ARGX
19.2
220%
0.1
P/E Multiple
Earnings Growth P/E to Growth
AU
PYC Therapeutics Ltd
ASX:PYC
Average P/E: 211.7
Negative Multiple: -18.1
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -180 740.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
61.1
413%
0.1
US
Amgen Inc
NASDAQ:AMGN
33.5
73%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
915.4
77%
11.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -213.4
48%
N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -472.7 N/A N/A
AU
CSL Ltd
ASX:CSL
31.8
65%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.6
44%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -54.7 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -134.7 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
AU
PYC Therapeutics Ltd
ASX:PYC
Average EV/EBITDA: 16.2
Negative Multiple: -16.5
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -219 476 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.2
29%
0.5
US
Amgen Inc
NASDAQ:AMGN
16
62%
0.3
US
Gilead Sciences Inc
NASDAQ:GILD
10.2
16%
0.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21
43%
0.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -514.8 N/A N/A
AU
CSL Ltd
ASX:CSL
19.7
42%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.1
35%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.8 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -108.7 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
AU
PYC Therapeutics Ltd
ASX:PYC
Average EV/EBIT: 21.2
Negative Multiple: -16.5
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -216 971.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.4
90%
0.3
US
Amgen Inc
NASDAQ:AMGN
30.4
90%
0.3
US
Gilead Sciences Inc
NASDAQ:GILD
10.2
32%
0.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.1
45%
0.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -501.1 N/A N/A
AU
CSL Ltd
ASX:CSL
24.6
54%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.7
42%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -53 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -79.2 N/A N/A

See Also

Discover More
Back to Top